Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...
A large US claims analysis links out-of-pocket medication costs with adherence and discontinuation patterns among patients ...
A systematic review and meta-analysis finds that weight-loss interventions are associated with decreased psoriasis severity ...
And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...
Researchers have uncovered a previously unrecognized role for immune cell surface sugars in driving inflammation in psoriasis. Scientists have refined how they understand the role of sugars called ...
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...
FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses and FDA filing plans.
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of more than $200 million in the first nine months of this year, zasocitinib is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback